Exhibit 99.1

OFFICE OF THE UNITED STATES TRUSTEE - REGION 3
POST-CONFIRMATION QUARTERLY SUMMARY REPORT

This Report is to be submitted for all bank accounts that are presently maintained by the post confirmation debtor.

Debtor's Name: Nuo Therapeutics, Inc.                                                             Bank: Capital One

Bankruptcy Number: 16-10192 (MFW)                                                            Account Number: All accounts

Date of Confirmation: May 5, 2016 (Effective Date)                                        Account Type: checking (operating), money market, CD

Reporting Period (month/year): October 1, 2016 – December 31, 2016

Beginning Cash Balance:	$	3,928,729
All receipts received by the debtor:
Cash Sales:	$	22,965
Collection of Accounts Receivable:	$	637,699
Proceeds from Litigation (settlement or otherwise):	$	0
Sale of Debtor's Assets:	$	100,000
Capital Infusion pursuant to the Plan:	$	0
Total of cash received:	$	760,664

Total of cash available:                                                                                                                                                                                                                                                                                                                                                                                                $    4,689,393

Less all disbursements or payments (including payments made under the confirmed plan) made by the Debtor:

Disbursements made under the plan, excluding the administrative

claims of bankruptcy professionals:                                                                                                                                                                                                                                                                                                                               $             4,172

Disbursements made pursuant to the administrative claims of

bankruptcy professionals:                                                                                                                                                                                                                                                                                                                                               $                   0

All other disbursements made in the ordinary course:                                                                                                                                                                                                                                                                                                                      $     2,011,708

Total Disbursements                                                                                                                                                                                                                                                                                                                                                                                                    $     2,015,880

Ending Cash Balance                                                                                                                                                                                                                                                                                                                                                                                                                     $     2,673,513

Pursuant to 28 U.S.C. Section 1746(2), I hereby declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge and belief.

01-31-2017                                                                             /s/ David E. Jorden 

Date                                                                                        David E. Jorden - CEO/CFO

Debtor: Nuo Therapeutics, Inc.
Case Number: 16-10192

In re Nuo Therapeutics, Inc.	Case No. 16-10192 (MFW)
Debtor	Reporting Period: December 31, 2016

QOR

CONSOLIDATED BALANCE SHEET (UNAUDITED) ¹

Line item	Current period
ASSETS
Current assets
Cash and cash equivalents and restricted cash		2,673,513
Accounts receivable		101,054
Other receivables		576,069
Inventory		75,358
Deposits		170,229
Prepaid expenses		230,071
Deferred costs, current portion		-
Total current assets		3,826,294
Property, plant and equipment
Aurix centrifuges		405,096
Computer and office equipment		17,436
Furniture and fixtures		31,452
Production equipment		34,899
Leasehold improvements		404,265
Software		257,619
Less: Accumulated depreciation		(664,651	)
Net property, plant and equipment		486,116
Other assets
Investment, Aldagen 1		-
Intangible assets, net of accumulated amortization		7,840,408
Goodwill		2,079,284
Other long-term assets		278,730
Total other assets		10,198,422
TOTAL ASSETS		14,510,832
LIABILITIES AND OWNERS' EQUITY
Liabilities not subject to compromise
Accounts payable		410,553
Accrued compensation and benefits		90,374
Accrued expenses		836,323
Accrued taxes		18,655
Customer deposits		-
Other long-term liabilities		123,434
Total liabilities not subject to compromise		1,479,339
Liabilities subject to compromise
Accounts payable		27,799
Accrued compensation and benefits		-
Accrued expenses		612
Accrued taxes		16,722
Customer deposits		70,737
Other long-term liabilities		-
Total liabilities subject to compromise		115,870
Shareholders' equity
Common stock		993
Preferred Stock		3
Additional paid-in capital		18,105,657
Retained earnings / (losses), post-emergence		(5,191,030	)
Total shareholders' equity		12,915,623
TOTAL LIABILITIES AND OWNERS' EQUITY		14,510,832

1. The accounting systems are not principally designed to produce reports that are consistent with the requirements of the Office of the United States Trustee. The numbers presented in this schedule are subject to change as additional information is made available. The information contained herein is provided to fulfill the requirements of the Office of the United States Trustee. All information contained herein is unaudited, subject to future adjustments and should not be considered as consistent with generally accepted accounting principles (GAAP). NOTE: The unaudited balance sheet reported for December 31, 2016, includes the accounts of Nuo Therapeutics, Inc. and its wholly-owned and controlled subsidiary Aldagen, Inc. ("Aldagen"). All significant inter-company accounts and transactions have been eliminated in consolidation.